Details

Autor(en) / Beteiligte

• McAuley, Daniel F
• Laffey, John G
• O'Kane, Cecilia M
• Perkins, Gavin D
• Mullan, Brian
• Trinder, T. John
• Johnston, Paul
• Hopkins, Philip A
• Johnston, Andrew J
• McDowell, Cliona
• McNally, Christine

Titel

Simvastatin in the Acute Respiratory Distress Syndrome

Ist Teil von

• The New England journal of medicine, 2014-10, Vol.371 (18), p.1695-1703

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In this study, patients with acute respiratory distress syndrome who were not receiving statins were assigned to receive simvastatin or placebo. At 28 days, there were no significant between-group differences in survival or in the number of ventilator-free days. The acute respiratory distress syndrome (ARDS) is a common, devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and by multiple organ failure. In ARDS there is an uncontrolled inflammatory response that results in alveolar damage, with the exudation of protein-rich pulmonary-edema fluid in the alveolar space that results in respiratory failure. 1 The inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with statins has been shown to modify a number of the underlying mechanisms implicated in the development of ARDS. 2 Statins decrease inflammation and histologic evidence of lung injury in murine models of ARDS. 3 Simvastatin reduced pulmonary and systemic . . .